Contributions of capsule, lipoproteins and duration of colonisation towards the protective immunity of prior Streptococcus pneumoniae nasopharyngeal colonisation

Vaccine

Volumn 30, Issue 30, 2012, Pages 4453-4459

  Cohen, Jonathan M ^a,b   Chimalapati, Suneeta ^a   de Vogel, Corné ^c   van Belkum, Alex ^c,d   Baxendale, Helen E ^b,e   Brown, Jeremy S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d BIOMÉRIEUX   (France)

^e PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

Antibody; Auxotroph; Capsule; Colonisation; Lipoprotein; Streptococcus pneumoniae

Indexed keywords

4 AMINOBENZOIC ACID; BACTERIAL PROTEIN; DRINKING WATER; IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ARTICLE; AUXOTROPHIC MUTANT; BACTERIAL COLONIZATION; BACTERIAL LOAD; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIUM CULTURE; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NASOPHARYNGEAL COLONIZATION; NONHUMAN; PRIORITY JOURNAL; SERUM BACTERICIDAL ANTIBODY ASSAY; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; BACTERIAL PROTEINS; IMMUNOGLOBULIN G; LIPOPROTEINS; MICE; NASOPHARYNX; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; VACCINES, ATTENUATED;

EID: 84862004873     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.080     Document Type: Article

References (28)

1. van der Poll T., Opal S.M. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009, 374(9700):1543-1556.
2. Bogaert D., de Groot R., Hermans P.W. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infectious Diseases 2004, 4(3):144-154.
3. Malley R. Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development. Journal of Molecular Medicine 2010, 88(2):135-142.
4. Flasche S., Van Hoek A.J., Sheasby E., Waight P., Andrews N., Sheppard C., et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Medicine 2011, 8(4):e1001017.
5. Cohen J.M., Khandavilli S., Camberlein E., Hyams C., Baxendale H.E., Brown J.S. Protective contributions against invasive Streptococcus pneumoniae pneumonia of antibody and Th17-cell responses to nasopharyngeal colonisation. PLoS One 2011, 6(10):e25558.
6. Roche A.M., King S.J., Weiser J.N. Live attenuated Streptococcus pneumoniae strains induce serotype-independent mucosal and systemic protection in mice. Infection and Immunity 2007, 75(5):2469-2475.
7. Richards L., Ferreira D.M., Miyaji E.N., Andrew P.W., Kadioglu A. The immunising effect of pneumococcal nasopharyngeal colonisation; protection against future colonisation and fatal invasive disease. Immunobiology 2010, 215:251-263.
8. Hyams C., Camberlein E., Cohen J.M., Bax K., Brown J.S. The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infection and Immunity 2010, 78(2):704-715.
9. Moyle P.M., Toth I. Self-adjuvanting lipopeptide vaccines. Current Medicinal Chemistry 2008, 15(5):506-516.
10. Lugade A.A., Bianchi-Smiraglia A., Pradhan V., Elkin G., Murphy T.F., Thanavala Y. Lipid motif of a bacterial antigen mediates immune responses via TLR2 signaling. PLoS ONE 2011, 6(5):e19781.
11. Chimalapati S., Cohen J., Camberlein E., Durmort C., Baxendale H.E., de Vogel C., et al. Infection with conditionally virulent Streptococcus pneumoniae Δpab strains induces antibody to conserved protein antigens but does not protect against systemic infection with heterologous strains. Infection and Immunity 2011, 79(12):4965-4976.
12. Moffitt K.L., Gierahn T.M., Lu Y.J., Gouveia P., Alderson M., Flechtner J.B., et al. TH17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host & Microbe 2011, 9(2):158-165.
13. Petit C.M., Brown J.R., Ingraham K., Bryant A.P., Holmes D.J. Lipid modification of prelipoproteins is dispensable for growth in vitro but essential for virulence in Streptococcus pneumoniae. FEMS Microbiology Letters 2001, 200(2):229-233.
14. Morona J., Miller D., Morona R., Paton J. The effect that mutations in the conserved capsular polysaccharide biosynthesis genes cpsA, cpsB, and cpsD have on virulence of Streptococcus pneumoniae. Journal of Infectious Diseases 2004, 189(10):1905-1913.
15. Basavanna S., Khandavilli S., Yuste J., Cohen J.M., Hosie A.H., Webb A.J., et al. Screening of Streptococcus pneumoniae ABC transporter mutants demonstrates that LivJHMGF, a branched-chain amino acid ABC transporter, is necessary for disease pathogenesis. Infection and Immunity 2009, 77(8):3412-3423.
16. Brown J.S., Gilliland S.M., Holden D.W. A Streptococcus pneumoniae pathogenicity island encoding an ABC transporter involved in iron uptake and virulence. Molecular Microbiology 2001, 40(3):572-585.
17. Yuste J., Botto M., Bottoms S.E., Brown J.S. Serum amyloid P aids complement-mediated immunity to Streptococcus pneumoniae. PLoS Pathogens 2007, 3(9):e120.
18. Shoma S., Verkaik N.J., de Vogel C.P., Hermans P., van Selm S., Mitchell T.J., et al. Development of a multiplexed bead-based immunoassay for the simultaneous detection of antibodies to 17 pneumococcal proteins. European Journal of Clinical Microbiology and Infectious Diseases 2011, 30(4):521-526.
19. Goldblatt D., Hussain M., Andrews N., Ashton L., Virta C., Melegaro A., et al. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. Journal of Infectious Diseases 2005, 192(3):387-393.
20. Soininen A., Pursiainen H., Kilpi T., Käyhty H. Natural development of antibodies to pneumococcal capsular polysaccharides depends on the serotype: association with pneumococcal carriage and acute otitis media in young children. Journal of Infectious Diseases 2001, 184(5):569-576.
21. McCool T.L., Cate T.R., Tuomanen E.I., Adrian P., Mitchell T.J., Weiser J.N. Serum immunoglobulin G response to candidate vaccine antigens during experimental human pneumococcal colonization. Infection and Immunity 2003, 71(10):5724-5732.
22. van Rossum A.M., Lysenko E.S., Weiser J.N. Host and bacterial factors contributing to the clearance of colonization by Streptococcus pneumoniae in a murine model. Infection and Immunity 2005, 73:7718-7726.
23. Zhang Z., Clarke T.B., Weiser J.N. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. Journal of Clinical Investigation 2009, 119(7):1899-1909.
24. Davis K.M., Nakamura S., Weiser J.N. Nod2 sensing of lysozyme-digested peptidoglycan promotes macrophage recruitment and clearance of S. pneumoniae colonization in mice. Journal of Clinical Investigation 2011, 121(9):3666-3676.
25. Malley R., Henneke P., Morse S.C., Cieslewicz M.J., Lipsitch M., Thompson C.M., et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(4):1966-1971.
26. McNeela E.A., Burke A., Neill D.R., Baxter C., Fernandes V.E., Ferreira D., et al. Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. PLoS Pathogens 2010, 6(11):e1001191.
27. Witzenrath M., Pache F., Lorenz D., Koppe U., Gutbier B., Tabeling C., et al. The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. Journal of Immunology 2011, 187(1):434-440.
28. Kim E., Choi S., Kwon M., Tran T.D., Park S.S., Lee K.J., et al. Streptococcus pneumoniae pep27 mutant as a live vaccine for serotype-independent protection in mice. Vaccine 2012, 30:2008-2019.